Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VE-1919
- Development stage
- Preclinical
- Lead developer
- Verseon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VE-1919 is a preclinical small-molecule drug candidate being developed by Verseon for the treatment of liver disease. The drug was designed using Verseon's proprietary computational platform, which combines molecular physics modeling and artificial intelligence (VersAI) to engineer novel chemical structures atom-by-atom. VE-1919 is currently in the optimization phase of preclinical development, targeting an undisclosed biological pathway involved in liver disease.
Beyond the preview
Go deeper on VE-1919.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VE-1919.